Bibliography
- International Centre for Medicines Research, “The CMR International 2004 R&D Factbook.” 2004
- Kola I, Landis J. Can the pharmaceutical industry reduce attrition rates? Nat Rev Drug Discov 2004;3(8):711-5
- Kramer JA, Sagartz JE, Morris DL. The application of discovery toxicology and pathology towards the design of safer pharmaceutical lead candidates. Nat Rev Drug Discov 2007;6(8):636-49
- Fielden MR, Kolaja KL. The role of early in vivo toxicity testing in drug discovery toxicology. Expert Opin Drug Saf 2008;7(2):107-10
- Helvig C, et al. Suicide inactivation of cytochrome P450 by midchain and terminal acetylenes. A mechanistic study of inactivation of a plant lauric acid omega-hydroxylase. J Biol Chem 1997;272(1):414-21
- Nakajima M, et al. Isoform selective inhibition and inactivation of human cytochrome P450s by methylenedioxyphenyl compounds. Xenobiotica 1999;29(12):1191-202
- Bencz Z, Ivan E, Cholnoky E. Analysis of cataract and keratotic damage induced by 4-diethylaminoethoxy-alpha-ethyl-benzhydrol (RGH-6201) in rats. Arch Toxicol Suppl 1985;8:476-9
- Menard J. The 45-year story of the development of an anti-aldosterone more specific than spironolactone. Mol Cell Endocrinol 2004;217(1-2):45-52
- Barnes BJ, Howard PA. Eplerenone: a selective aldosterone receptor antagonist for patients with heart failure. Ann Pharmacother 2005;39(1):68-76
- Lee SS, et al. Targeted disruption of the alpha isoform of the peroxisome proliferator-activated receptor gene in mice results in abolishment of the pleiotropic effects of peroxisome proliferators. Mol Cell Biol 1995;15(6):3012-22
- Adgey AA. Bleeding complications with new antithrombotics used in ischaemic heart disease. Haemostasis 1996;26(5):237-46
- Tabacova S. Mode of action: angiotensin-converting enzyme inhibition – developmental effects associated with exposure to ACE inhibitors. Crit Rev Toxicol 2005;35(8-9):747-55
- Hilgers KF, et al. Aberrant renal vascular morphology and renin expression in mutant mice lacking angiotensin-converting enzyme. Hypertension 1997;29(1 Pt 2):216-21
- Zambrowicz BP, Turner CA, Sands AT. Predicting drug efficacy: knockouts model pipeline drugs of the pharmaceutical industry. Curr Opin Pharmacol 2003;3(5):563-70
- Rudmann DG, Durham SK. Utilization of genetically altered animals in the pharmaceutical industry. Toxicol Pathol 1999;27(1):111-4
- Martin M, Reidhaar-Olson JF, Rondinone CM. Genetic association meets RNA interference: large-scale genomic screens for causation and mechanism of complex diseases. Pharmacogenomics 2007;8(5):455-64
- Berg AL, Bohlooly YM. The program for phenotyping of genetically modified animals at AstraZeneca. Exp Toxicol Pathol 2006;57(5-6):383-4
- Foster WR, et al. A retrospective analysis of toxicogenomics in the safety assessment of drug candidates. Toxicol Pathol 2007;35(5):621-35
- Nomanbhoy TK, et al. Inhibitor focusing: direct selection of drug targets from proteomes using activity-based probes. Assay Drug Dev Technol 2003;1(1 Pt 2):137-46
- Olson H, et al. Concordance of the toxicity of pharmaceuticals in humans and in animals. Regul Toxicol Pharmacol 2000;32(1):56-67
- Tateno C, et al. Near completely humanized liver in mice shows human-type metabolic responses to drugs. Am J Pathol 2004;165(3):901-12
- Dieckhaus CM, et al. Negative ion tandem mass spectrometry for the detection of glutathione conjugates. Chem Res Toxicol 2005;18(4):630-8
- Vickers AE, et al. Kidney slices of human and rat to characterize cisplatin-induced injury on cellular pathways and morphology. Toxicol Pathol 2004;32(5):577-90
- Luyendyk JP, et al. Unique gene expression and hepatocellular injury in the lipopolysaccharide-ranitidine drug idiosyncrasy rat model: comparison with famotidine. Toxicol Sci 2006;90(2):569-85
- Roth RA, Ganey PE. Successes and frustrations in developing animal models of idiosyncratic drug reactions. Chem Biol Interact 2005;152(2-3):165; author reply 167-8
- Park BK, Pirmohamed M, Kitteringham NR. Role of drug disposition in drug hypersensitivity: a chemical, molecular, and clinical perspective. Chem Res Toxicol 1998;11(9):969-88
- Walgren JL, Mitchell MD, Thompson DC. Role of metabolism in drug-induced idiosyncratic hepatotoxicity. Crit Rev Toxicol 2005;35(4):325-61
- Mitchell MD, et al. Peptide-based in vitro assay for the detection of reactive metabolites. Chem Res Toxicol 2008;21(4):859-68
- Pharmaceutical Research and Manufacturers of America, Pharmaceutical Industry Profile. Washington DC: PhRMA; 2007
- DiMasi JA, Hansen RW, Grabowski HG. The price of innovation: new estimates of drug development costs. J Health Econ 2003;22(2):151-85